
Genoskin and PharmaJet Announce Strategic Research Partnership to Advance Precision Vaccine Delivery
Genoskin, a leading Franco-American TechBio company specializing in bio-stabilized immunocompetent human skin platforms, and PharmaJet, an innovative provider of Precision Delivery Systems (PDS), announce a strategic research partnership during the World Vaccine Congress.
Read more
Drug delivery is constantly changing – and the materials to support new applications must continue to evolve as well. Meeting current and future needs requires innovative materials to overcome age-old familiar hurdles and Covestro experts are leading the way.
Read more
Everyone is tired of being jabbed, but today, that’s the predominant option for vaccination. In the near future, however, the painful jab and muscle soreness that persists for days will be eliminated by needleless vaccines that - at least in some cases - provide more robust protection.
Read more
Messenger RNA (mRNA) technology has been central to the global response to Covid-19, enabling rapid manufacture of effective vaccines. But the virus continues to evolve, learning to out-maneuver prior immunity, whether from infection or from vaccination.
Read more
Over the last two years, there has been an unprecedented frenzy to develop new vaccines due to the COVID-19 pandemic, but DNA vaccines have rather stood in the shadow of their mRNA cousins.
Read more
As India nears the rollout of ZyCoV-D, the world's first DNA-based, needle-free Covid vaccine for individuals aged 12 years and above, one Bengaluru trial site gave the low-down on how the much talked about jab works.
Read more
The ZyCoV-D vaccine heralds a wave of DNA vaccines for various diseases that are undergoing clinical trials around the world.
Read more
We take a look at some of the COVID-19 vaccine candidates moving through clinical trials.
Read more
On Friday, the Indian government authorized a needle-free Covid-19 vaccine developed by an indigenous pharmaceutical company.
Read more
New Delhi: A decision on the approval of Zydus Cadila's COVID-19 vaccine Zydus Cov-D is expected soon...
Read more
ZyCov-D when approved will help not only adults but also adolescents in the 12 to 18 years age group
Read more
Researchers are set to commence the first Phase 1 human trial ...
Read more












